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In vivo effectiveness and safety of
probiotics on prophylaxis and treatment of
oral candidiasis: a systematic review and
meta-analysis
Lijun Hu1, Mimi Zhou1, Andrew Young2, Weiwei Zhao1 and Zhimin Yan1*
Abstract
Background: To systematically review and assess the in vivo effectiveness and safety of probiotics for prophylaxis
and treating oral candidiasis.
Methods: A literature search for studies published in English until August 1, 2018 was conducted in the following
databases: PubMed, EMBASE, Cochrane Library, and Web of Science. Randomized controlled clinical trials and
experimental mouse animal model studies comparing probiotics (at any dosage and in any form) with control
groups (placebo, blank control or other agents) and reporting outcomes of the prophylactic and therapeutic effects
were considered for inclusion. A descriptive study and, potentially, a meta-analysis were planned.
Results: Six randomized controlled clinical trials and 5 controlled experiments of mouse animal models were
included in the systematic review. Four randomized controlled clinical trials comparing a probiotics group with a
placebo/blank control group in 480 elderly and denture wearers were included in the meta-analysis. The overall
combined odds ratio of the (random effects) meta-analysis was 0.24 (95% CI =0.09–0.63, P < 0.01). The overall
combined odds ratio of the (fixed effects) sensitivity analysis was 0.39 (95% CI =0.25–0.60, P < 0.01) by excluding a
study with the smallest sample size. These analyses showed that there was a statistically significant difference in the
effect of probiotics compared with the control groups in elderly and denture wearers. The remaining 2 studies
compared probiotics with other agents in a population aged 18–75 years and children aged 6–14 years respectively,
and were analyzed descriptively. Meta-analysis and descriptive analyses indicated that probiotics were potentially
effective in reducing morbidity, improving clinical symptoms and reducing oral Candida counts in oral candidiasis.
The biases of the included studies were low or uncertain. The relatively common complaints reported were
gastrointestinal discomfort and unpleasant taste, and no severe adverse events were reported.
Conclusions: Probiotics were superior to the placebo and blank control in preventing and treating oral candidiasis in
the elderly and denture wearers. Although probiotics showed a favorable effect in treating oral candidiasis, more
evidence is required to warrant their effectiveness when compared with conventional antifungal treatments.
Moreover, data on the safety of probiotics are still insufficient, and further research is needed.
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Background
Oral candidiasis (OC) is a fungal infection considered to
be the most common oral mucosal infectious disease [1]
and is mainly caused by Candida albicans. The detec-
tion rate of C. albicans in the general population is 20 to
75% [2–5]. It has also been reported that 15 to 71% of
denture wearers [3, 6, 7] and 80 to 95% of HIV-infected
individuals suffer from oral candidiasis [8–10]. The ac-
cepted treatment for oral candidiasis is the use of antifun-
gal agents, such as nystatin, fluconazole, or miconazole.
[11]. Because of adverse effects and side effects, such as
the subsequent resistance of candida to antifungal agents,
dysgeusia, and gastrointestinal discomfort, including
nausea, vomiting and diarrhea, the clinical application
of antifungal drugs can be limited [12]. Therefore, the
exploration of new prophylaxis and therapeutic strat-
egies for oral candidiasis is indicated.
Previous studies have reported that probiotics have ef-
fects on vulvovaginal candidiasis [13], dermatophytosis
[14], gastrointestinal infections [15], hypertension [16]
and colorectal cancer [17–19]. Known mechanisms of
probiotics include regulating innate and acquired im-
munity and releasing antioxidants and bacteriocins to
restore the balance of the microbial community and the
immune system [20–22]. Meanwhile, it is also reported
that probiotics are potentially promising treatment for
oral diseases such as periodontal disease, dental caries,
halitosis and oral candidiasis [23].
Over the last few years, probiotics have been demon-
strated to enable the regulation of the oral microbiota
[24]. Studies have shown that Lactobacillus rhamnosus
[25], Lactobacillus reuteri [26], etc. can reduce oral
Candida counts. However, the estimated effects of pro-
biotics in the treatment of oral candidiasis are conflict-
ing [25–27]. Additionally, information on the safety of
probiotics is lacking. Therefore, the aim of this review is
to assess the effectiveness and safety of probiotics in the
prophylaxis and treatment of oral candidiasis using a
meta-analysis and systematic evaluation.
Methods
Data sources and search strategy
This systematic review was performed according to the
recommendations of the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) [28].
Two of the authors (L.J. H and M.M. Z) independently
searched the following electronic databases: PubMed,
EMBASE, the Cochrane Library, and Web of Science for
articles published from inception to August 1, 2018. The
following terms were searched in combination: (“probio-
tics” OR “probiotic”) AND (“oral candidiasis” OR “oral
candidiases” OR “oral moniliasis” OR “oral moniliases”
OR “oral candida” OR “thrush”). Manual searches of the
reference and citations of the identified studies were also
conducted as a supplement.
Study selection criteria
The inclusion criteria were as follows: (I) original stud-
ies; (II) randomized controlled clinical trials or experi-
mental mouse animal model controlled studies; (III)
studies that compared probiotics (at any dosage and in
any form) with control groups (placebo, blank control or
other drugs); (IV) studies that reported specific out-
comes of the therapeutic effect, such as the counts of
candida and/or clinical improvement; and (V) studies
published in the English language. Studies written in lan-
guages other than English, review articles, letters to the
editor, meeting summaries, patented inventions, unpub-
lished articles and articles that did not have full-text
available were excluded.
Data extraction
The two investigators (L.J. H and M.M. Z) independently
identified the titles and abstracts that potentially met the
inclusion criteria. Then, full-text articles were read for a
complete assessment and determination of inclusion or
exclusion. Each investigator independently performed
the above steps. If the two review authors could not
reach a consensus regarding inclusion, a third reviewer
(Z.M. Y or A. Y) was invited to conduct an assessment
and settle any disagreements. For each included article,
data such as age, gender/sex, sample size, interventions,
follow-up time and outcome indicators were extracted
and summarized in a table format.
Risk of bias of the included studies
Three investigators (L.J. H, M.M. Z, and W.W. Z) evalu-
ated the clinical studies based on the criteria of the
Cochrane handbook for systematic reviews of interven-
tions using Review Manager 5.2 (Cochrane IMS, Oxford,
UK). The considered biases were as follows: (I) random
sequence generation (selection bias); (II) allocation con-
cealment (selection bias); (III) blinding of participants
and personnel (performance bias); (IV) blinding of out-
come assessment (detection bias); (V) incomplete out-
come data (attrition bias); and (VI) selective reporting
(reporting bias).
For studies using animal models, the quality evalu-
ation was based on the Collaborative Approach to
Meta Analysis and Review of Animal Data from
Experimental Studies (CAMARADES) [29]. The con-
sidered biases were as follows: (I) sample size calcu-
lation; (II) randomization of treatment or control;
(III) blinded assessment of outcome; (IV) allocation
concealment; (V) use of suitable animals; (VI) avoid-
ance of anesthetics with marked intrinsic properties;
(VII) statement of control of temperature; (VIII)
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statement of compliance with regulatory require-
ments; (IX) publication in a peer-reviewed journal;
and (X) statement regarding possible conflicts of
interest.
Statistical analysis
Review Manager 5.2 was used to perform the meta-
analyses. We assessed the therapeutic effect of probiotics
on oral candidiasis by means of odds ratios (ORs) and
their 95% confidence intervals (CIs) using Mantel-
Haenszel statistics. Statistical heterogeneity analysis of
the included studies was performed using the I2 metric.
When I2 < 50%, the studies were considered to be suffi-
ciently homogeneous, and a fixed effect model was used.
In contrast, when there was heterogeneity among the
studies, a random effects model was used, and sensitivity
analysis was conducted to achieve homogeneity among
the included studies.
For the smaller group of studies with poor homogen-
eity and for data provided by studies that could not be
analyzed by meta-analysis, descriptive analysis and
evaluation (i.e., qualitative analysis) was performed.
Results
Clinical research
Characteristics of the included studies
The number of included clinical studies was 6, which in-
volved a total of 605 subjects (Fig. 1). The data extracted
from each study are summarized in Table 1.
Four of these studies, including 480 elderly and den-
ture wearers, compared the effects of therapy between
the probiotics group and the blank or placebo group,
and a meta-analysis was performed [25–27, 30]. The
study by TY Miyazima et al. subdivided the probiotics
group into the T1 probiotics group using Lactobacillus
acidophilus NCFM and the T2 probiotics group using L.
rhamnosus Lr-32 [30]. Given the existing heterogeneity
of the interventions, this study combined the T1 probio-
tics group and T2 probiotics group as one group in the
meta-analysis.
Two of these studies were excluded in the meta-
analysis and were evaluated by descriptive analysis due
to the comparison of probiotics with other agents. The
study by Duo Li et al. evaluated the short-term effective-
ness and safety of probiotics in a population aged 18–75
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Fig. 1 Trial flow and study selection
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antifungal agents—sodium bicarbonate solution and ny-
statin—as well as Bifidobacterium longum, Lactobacillus
bulgaricus and Streptococcus thermophilus) with a con-
trol group (received only topical antifungal agents) [31].
The trial by Rahul Mishra et al. compared the antimicro-
bial effect of probiotics in children aged 6–14 years with
herbal rinse and commonly used antimicrobial agents of
0.2% chlorhexidine [32]. However, the types of probiotics
contained in the probiotic product were not mentioned
in the article.
Quality of the included studies
According to the Cochrane risk of bias assessment cri-
teria, the included studies failed to achieve all seven as-
pects in detail. The quality evaluations of the studies are
listed in Table 2. The overall risk of each type of bias is
presented in Fig. 2, and the risk of each bias in each of
the included studies is presented in Fig. 3. The risk of
bias assessment for the included studies was conducted
by 2 independent researchers (L.J. H and M.M. Z), and
the consistency of the assessment results was 100%.
Effectiveness assessment
Meta-analysis was performed on 4 studies with a total of
480 subjects that compared a probiotics group with a
placebo or blank control group [25–27, 30]. The hetero-
geneity analysis of these 4 studies yielded x2 = 13.41,
P = 0.004, and I2 = 78%. The random effects model
analysis showed that there was a statistically signifi-
cant difference in the effect of probiotics for prevent-
ing and treating oral candidiasis in elderly and denture
wearers compared with the control groups (OR = 0.24,
95% CI =0.09–0.63, P < 0.01; Fig. 4).
Sensitivity analysis was performed in the meta-
analysis. After removing 1 study with the smallest sam-
ple size, the remaining 3 studies were of good homogen-
eity with an I2 value of 0% [27]. The fixed effect model
analysis showed that there was a statistically significant
difference in the effect of probiotics compared with the
control groups in elderly and denture wearers (OR =
0.39, 95% CI =0.25–0.60, P < 0.01; Fig. 5). Thus, taken
together, the meta-analysis indicated that probiotics may
be potentially effective for oral candidiasis in the elderly
and denture wearers.
In addition, two studies compared the effect of probio-
tics with other drugs, including the combination of ny-
statin paste and a sodium bicarbonate solution, Chinese
herbal rinse and 0.2% chlorhexidine digluconate rinse
[31, 32]. Although hyperemia of the probiotics group
using the combination of probiotics, nystatin paste and
sodium bicarbonate solution improved after 4 weeks of
follow-up, it did not show significant differences com-
pared with the control group without probiotics.
However, the detection rate of Candida spp. in the
probiotics group (8.2%) was significantly lower than
in the control group (34.6%) in this population aged
















Hatakka et al., 2007 [25] Low risk Uncertain Low risk Uncertain Low risk Low risk Uncertain
Ishikawa et al., 2015 [27] Uncertain Uncertain Low risk Low risk Low risk Low risk Low risk
Kraft-Bodi et al., 2015 [26] Low risk Low risk Low risk Low risk Uncertain Low risk Low risk
Miyazima et al., 2017 [30] Uncertain Uncertain Low risk Uncertain Low risk Low risk Low risk
Li et al., 2014 [31] Low risk Uncertain High risk High risk Low risk Low risk Low risk
Mishra et al., 2016 [32] Uncertain Uncertain Low risk Uncertain Low risk Low risk Uncertain
Fig. 2 Risk of bias graph: the overall risk of each bias is presented as a percentage representing the risk in all the included studies
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18–75 years (P = 0.038) [31]. Therefore, probiotics
helped to improve the clinical symptoms of oral can-
didiasis and reduce the detection rate of Candida
spp. more than using antifungal drugs alone. The
0.2% chlorhexidine digluconate rinse group had the
best effects in terms of decreasing the number of C.
albicans colony-forming units (CFUs) per milliliter in
children aged 6–14 years (P < 0.01), followed by the
probiotics group (P < 0.01), and the poorest outcome
was from the Chinese herbal rinse (P > 0.01) [32].
From the above information, probiotics exhibit the
potential effect of inhibiting the colonization of Can-
dida on the surface of oral mucosa and improving
the clinical signs and symptoms of fungal infections.
Safety evaluation
Only 2 of the 6 studies included information about ad-
verse events or complaints with probiotics [26, 31]. One
study reported that the probiotic had no adverse events
[31], while the other reported that its most common
complaints were an unpleasant taste and gastric discom-
fort, with incidences of 6 and 2.87%, respectively, but no
severe adverse events were reported [26].
Animal research
Through a literature search and screening, a total of
5 studies that met the criteria were included [33–37].
Table 3 lists the 5 studies and the data extracted,
which included publication date, sex, age and strain
of the mouse animal model, number of mice, method
of candida infection, probiotic species, method of
drug administration, intervention time, control group,
and outcome indicators. The bias assessment of the
included mouse animal model experiments is summa-
rized in Table 4.
Because the original data of Candida colony-forming
units per milliliter and symptom score could not be ob-
tained, a descriptive analysis was performed. First, com-
pared with the blank group, L. acidophilus, L. rhamnosus
and 3 × 109 CFU/ml of Streptococcus salivarius K12 all
showed the effect of reducing the Candida counts (P <
0.05) [33–35, 37]. In 2 studies conducted by Sanae A. Ishi-
jima et al., 1.5 × 109 CFU/ml and 3 × 109 CFU/ml of S. sali-
varius K12 and 15mg/ml and 30mg/ml of Enterococcus
faecalis all indicated an obviously significant difference
from the control group (P < 0.01) [34, 36]. Second, L.
rhamnosus could significantly reduce the Candida
counts compared with nystatin (P < 0.05) [33]. When
compared with fluconazole, a study reported that mice
Fig. 3 Risk of bias summary: the risk of each bias in each of the
included studies is shown separately. Note: +,?, − indicate high,
uncertain, and low bias, respectively
Fig. 4 Odds ratio and 95% confidence intervals from individual studies. Forest plots evaluating the effect of probiotics (random-effect model).
Note: events indicate the subjects with oral candidiasis
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given 15mg/ml of E. faecalis had a significant decrease in
fungal burden, although this was not observed to be a
complete cure [36]. These results showed that probiotics
had an effect in reducing oral Candida counts and redu-
cing the clinical signs and symptoms of fungal infections
in animal models.
Discussion
Attempting to treat oral candidiasis with probiotics has
gradually become a topic of considerable interest in re-
search. The clinical studies and animal model experi-
ments included in this review reported that probiotics
such as L. rhamnosus [25, 27, 30, 33, 37], Propionibacter-
ium freudenreichii [25], L. acidophilus [27, 30, 33, 35], L.
reuteri [26], B. longum [31], Bifidobacterium bifidum
[27], L. bulgaricus [31], S. thermophiles [31], L. fermen-
tum [35], S. salivarius K12 [34] and heat-killed E. faeca-
lis [36] have the effect of inhibiting the excessive growth
of Candida. Although the results of studies that met the
eligibility criteria appear to demonstrate that probiotics
have potential antifungal effects, the types of probiotics
selected in these studies were different, and some studies
focused on single probiotics [26, 30], while others focused
on a combination of multiple probiotics [25, 27, 31]. For
example, the study by TY Miyazima et al. reported that
using L. acidophilus or L. rhamnosus alone could reduce
oral Candida counts [30], while the study by Hatakka et
al. showed that the combined use of L. rhamnosus and P.
freudenreichii can reduce the risk of high yeast counts by
75% [25]. Additionally, in 2015, Ishikawa et al. indicated
that the combination of probiotics containing L. rhamno-
sus, L. acidophilus and B. bifidum reduced the level of
Candida colonization in dentures [27]. Since the types
and concentrations of probiotics varied between the stud-
ies included in this review, we were unable to determine
which species of probiotics and what specific doses are
optimal for treating oral candidiasis. Meanwhile, research
still needs to be done on which combinations of probiotics
have better curative effects and how probiotics work syn-
ergistically. It is worth noting, however, that the types of
probiotics in these 5 clinical studies [25–27, 30, 31] and 3
mouse-model experiments [34, 35, 37] were from the gen-
era Lactobacillus and Bifidobacterium.
Of the included studies, there were studies comparing
the effect of probiotics with conventional antifungal
treatments [31, 32]. Duo Li et al. reported that oral local
antifungal agents (2% sodium bicarbonate solution and
nystatin) plus local probiotics helped to improve certain
clinical conditions and reduce the detection rate of Can-
dida spp. [31]. Moreover, a study in 2016 demonstrated
that probiotic rinse was equally effective as 0.2% chlor-
hexidine digluconate rinse in reducing C. albicans
counts after 1 week of intervention [32]. However, there
is still insufficient evidence to prove that probiotics can
completely replace antifungal agents in the treatment of
oral candidiasis.
Of the 6 RCTs included, 3 evaluated the prophylaxis ef-
fect of probiotics in susceptible populations [25, 26, 32].
In total, in 366 elderly people from sheltered housing units
and nursing homes, probiotics of L. rhamnosus, P.
freudenreichii and L. reuteri were effective in reducing
Candida counts [25, 26]. In 60 children with carious teeth
(a predisposing factor of oral Candida carriage [38]), the
prophylactic effect of probiotics on oral candidiasis was
revealed [32]. The possible prophylactic mechanisms in-
cluded competition with pathogenic microorganisms for
nutrients and receptors [39, 40] and releasing external
metabolites and producing hydrogen peroxide (H2O2), an-
tagonizing the excessive growth of Candida [41, 42].
Based on current clinical studies, it is indicated that the
prophylactic use of probiotics might potentially reduce the
mobility of oral candidiasis and thus decrease the eco-
nomic burden of the disease.
In addition to commonly used probiotic species, an
animal experiment included in this review reported that
heat-killed E. faecalis had an immunostimulatory effect
in a murine model of oral candidiasis, which is beneficial
for the treatment of oral candidiasis [36]. Heat-treated E.
faecalis has been reported to have immunoenhancing ef-
fects that include increasing cell-mediated immunity,
Fig. 5 Sensitivity test: forest plot of odds ratio and 95% confidence intervals in studies at low risk of bias (fixed-effect model). Note: events indicate the
subjects with oral candidiasis
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humoral immunity, monocyte/macrophage function, and
natural killer cell activity in nonsensitized mice [43]. In
2012, an animal study aimed at the lysed E. faecalis in
the murine model of allergic rhinitis suggested that E.
faecalis has an immunoregulatory activity [44]. In a pilot
study, living nonpathogenic E. faecalis was shown to be
beneficial for the treatment of asthma [45]. However, no
study has investigated the clinical effect of E. faecalis on
oral candidiasis. This might open up a new research dir-
ection for the study of probiotics.
With respect to safety, the adverse events of probiotics
reported in the in vivo studies included in this system-
atic review were gastrointestinal discomfort and unpleas-
ant taste [26]. No severe adverse events were reported
from either the clinical trials or the animal studies. How-
ever, a report issued by the Agency for Healthcare Re-
search and Quality (AHRQ) in 2011 concluded that
although the existing clinical trials do not indicate an in-
creased risk, this does not necessarily confirm the safety
of probiotics in intervention studies with confidence
[46]. The theoretically possible side effects of probiotics
were systemic infections, deleterious metabolic activities,
excessive immune stimulation in susceptible individuals,
and gene transfer [47]. For instance, a study reported
that a newborn with an umbilical bulge developed sepsis
after a 10-day administration of Bifidobacterium breve
BBG01 [48]. In contrast, a study published in 2015 indi-
cated that probiotics are generally safe for most popula-
tions based on the preponderance of the data from
clinical trials, animal studies, and in vitro studies [49]. In
another study, 80 children aged 3 months to 3 years old
with rotavirus diarrhea were divided into placebo and
treatment groups. The treatment group given commer-
cial sachets of Bifidobacterium did not report adverse
events during or after treatment [50]. Moreover, Lacto-
bacillus, Bifidobacterium, and Enterococcus have been
used as food additives for a long period of time [51]. It
has been demonstrated that the widespread use of bever-
ages containing probiotics such as Lactobacillus and
Bifidobacterium can reduce the prevalence of oral can-
didiasis in healthy individuals [52]. Thus, the reports are
contradictory. Therefore, further research is still needed
to confirm the safety and to evaluate adverse events re-
lated to probiotics in healthy people or patients.
Although aimed at collecting the best evidence to date,
this review still had limitations. First, the inconsistency
of the evaluation criteria of the clinical effects among
studies might be a source of heterogeneity. The limited
number of trials and subjects was also a restriction.
More trials are needed to verify the results above. Second,
the standard for the prophylactic and therapeutic use of
probiotics has not been established, and the combination
of probiotics, dosages, dosing regimens, vehicles, adverse
reactions, biodynamics and cost-effectiveness of the
probiotics also need to be determined. Furthermore, al-
though probiotics are beneficial to humans, as a living bio-
logical agent, it is still necessary to consider biological
tolerance and whether probiotics are suitable for various
types of people, such as immunosuppressed patients, in-
fants and pregnant women. Much still needs to be learned
about this new treatment for oral candidiasis.
Conclusions
It is concluded in this systematic review that probiotics
were significantly superior to the placebo and blank con-
trol in preventing and treating oral candidiasis both in
clinical trials of elderly and denture wearers and in ani-
mal experiments, including inhibiting the colonization
of Candida on the surface of oral mucosa and reducing
the clinical signs and symptoms of fungal infections.
However, although probiotics showed a favorable effect
in treating oral candidiasis, more evidence is required to
confirm their effectiveness when compared with conven-
tional antifungal treatments. Moreover, although the
commonly reported adverse events of probiotics were
relatively mild, the evidence for safety is still insufficient,
and further research is needed.
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